What is the typical nighttime glucose profile from bedtime to early morning for an adult with type 2 diabetes mellitus and an HbA1c of 8% who is taking metformin 1000 mg twice daily and bedtime basal insulin glargine 20 units?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Nighttime Glucose Variation in Type 2 Diabetes with HbA1c 8%

For a patient with type 2 diabetes, HbA1c 8%, on metformin 1000 mg twice daily and bedtime insulin glargine 20 units, expect bedtime glucose around 153-177 mg/dL, with a nadir between 1:00-4:00 AM, and fasting glucose around 152-167 mg/dL. 1

Expected Nighttime Glucose Profile Table

Time Period Expected Glucose Range (mg/dL) Clinical Notes
Bedtime (23:00) 153-177 mg/dL Target bedtime glucose for HbA1c 7.0-7.99% [1]
Early Night (23:00-01:00) Gradual decline Period of highest risk for early hypoglycemia if bedtime glucose <153 mg/dL [2]
Overnight Nadir (01:00-04:00) Lowest glucose values Minimal hypoglycemia risk with glargine; stable insulin action [3]
Early Morning (04:00-07:30) Gradual rise toward fasting Dawn phenomenon may cause rise; second hypoglycemia risk window [2]
Fasting/Pre-breakfast (07:00-08:00) 152-167 mg/dL Target fasting glucose for HbA1c 7.5-7.99% [1]

Key Clinical Context

Baseline Glycemic Expectations

  • With HbA1c 8%, the average fasting glucose should be approximately 167 mg/dL (157-177 mg/dL) to correlate with this level of glycemic control 1
  • Bedtime glucose targets should be around 177 mg/dL (166-188 mg/dL) for patients at this HbA1c level 1
  • The current regimen (metformin + 20 units glargine) is likely underdosed, as typical basal insulin requirements range from 39-70 units daily in similar populations 3, 4

Nocturnal Glucose Pattern Characteristics

Insulin glargine provides relatively flat overnight coverage compared to NPH insulin, with maximum glucose lowering occurring just prior to the next injection regardless of timing 3

Two critical hypoglycemia risk windows exist: 2

  • Early night (23:00-01:00): Risk predicted by bedtime glucose <153 mg/dL
  • Early morning (04:00-07:30): Risk indicated by fasting glucose <5.5 mmol/L (99 mg/dL)
  • Minimal risk period (01:00-04:00): Lowest hypoglycemia occurrence

Treatment Optimization Considerations

The combination of metformin with basal insulin glargine reduces insulin requirements by approximately 17% compared to insulin alone while improving HbA1c by an additional 0.74% 5

For this patient at HbA1c 8%, insulin dose titration is clearly needed: 6

  • Current dose: 20 units
  • Expected requirement: 39-70 units based on clinical trial data 3
  • Titration algorithm: Increase by 2 units every 3 days targeting fasting glucose 80-130 mg/dL 6

Common Pitfalls to Avoid

Bedtime glucose monitoring is more reliable than 3:00 AM testing for preventing nocturnal hypoglycemia 2

  • Bedtime glucose >153 mg/dL prevents early-night hypoglycemia
  • Fasting glucose >99 mg/dL indicates absence of early-morning hypoglycemia

Symptomatic hypoglycemia is most common during the first 12 weeks of insulin initiation (4.1 episodes/patient-year with glargine + metformin), then decreases significantly 4

Pre-dinner hyperglycemia (glucose 8.6-10.1 mmol/L or 155-182 mg/dL) commonly persists with bedtime basal insulin alone, indicating need for additional prandial coverage or GLP-1 RA if HbA1c remains above goal 4

Related Questions

Please create a table of nighttime glucose values for an adult female with type II diabetes (HbA1c 8 %) who had a bedtime glucose of 126 mg/dL at 11:30 PM after 12 units of Lantus (insulin glargine), with the prior night bedtime glucose of 168 mg/dL after 16 units, a next‑morning glucose of 132 mg/dL, and overnight readings of 96 mg/dL at 1:50 AM and 102 mg/dL at 3:45 AM.
Should the insulin-to-carbohydrate ratio be reduced when initiating glipizide therapy?
What should a 61-year-old woman with diabetes do when she develops severe hyperglycemia after starting prednisone 10 mg twice daily for sciatica?
In a 46-year-old male with BMI 44 kg/m², type 2 diabetes, hypertension, hyperlipidemia, microalbuminuria (urine albumin excretion 680 mg/24 h), and an HbA1c of 13.5 % who is taking glipizide 10 mg twice daily and metformin extended‑release 1000 mg twice daily, what additional medication(s) should be added?
What is the appropriate next management for an 81‑year‑old woman with type 2 diabetes, hemoglobin A1c 6.9%, impaired renal function (elevated BUN, reduced eGFR) and significant albuminuria/proteinuria who is currently taking atenolol, aspirin, atorvastatin, gabapentin, insulin, semaglutide, and valsartan (Diovan)?
Can a low blood urea nitrogen (BUN) on a basic metabolic panel (BMP) be caused by dehydration?
Is it normal to have discoloration three weeks after a helix fusion (ear cartilage repair)?
What is the pharmacologic treatment for an acute gout attack?
Which multisystem disorder most likely explains a 29‑year‑old male with prior acute benign myositis, persistent hypotonia, failure to gain weight despite polyphagia, cold intolerance, recurrent infections, muscle weakness, ophthalmologic disturbances, anxiety, arrhythmia, brain fog, depression, polyuria/polydipsia with low serum osmolality, hypercalcemia with normal parathyroid hormone, suppressed thyroid‑stimulating hormone with normal free thyroxine, elevated testosterone, low aldosterone, low 17‑hydroxycorticosteroids, mild leukopenia and anemia?
What clinical findings differentiate peripheral vertigo from central vertigo?
How should a lactating or postpartum woman with a painless, smooth, mobile, well‑circumscribed breast lump diagnosed as a galactocele be managed?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.